M1 Receptor Modulators via Selective Oxazine Analog Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease and schizophrenia lack highly selective positive allosteric modulators for the M1 muscarinic acetylcholine receptor, leading to adverse effects due to non-selectivity, which hampers their efficacy and safety.
Innovation Solution
Development of N-substituted 3,4-dihydro-benzo[b][1,4]oxazine-2-carboxamide analogs as positive allosteric modulators of the M1 muscarinic acetylcholine receptor, which potentiate receptor activity without activating it directly, thereby reducing adverse effects and enhancing therapeutic outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective muscarinic receptor agonists are used to treat Alzheimer's disease and schizophrenia, then cognitive function may be improved, but adverse effects increase due to activation of multiple receptor subtypes
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (formula I) that are selectively active at the M1 muscarinic receptor subtype rather than activating all muscarinic receptor subtypes. This selective activity at the specific target location (M1 receptor) improves cognitive function while avoiding the adverse effects caused by non-selective activation of other receptor subtypes (M2, M3, M4, M5).
Solution Approach 2:
The patent utilizes parameter changes by modifying the molecular structure of muscarinic receptor ligands through systematic variation of substituents at specific positions (R1-R6, Q1-Q7) in formula I. These structural parameter changes create a series of analogs with optimized binding affinity and selectivity for the M1 receptor, thereby improving the therapeutic index by enhancing desired effects while reducing adverse effects.
2Reliability
If positive allosteric modulators are developed to enhance M1 receptor activity, then therapeutic selectivity improves, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the muscarinic receptor ligand molecule into distinct functional segments: a core oxazine-carboxamide structure (positions 1-4) and variable substituent groups (R1-R6, Q1-Q7) at specific positions. This segmentation allows independent optimization of each segment's contribution to binding affinity, selectivity, and pharmacological activity, thereby achieving high therapeutic selectivity while managing structural complexity through modular design.
Solution Approach 2:
The patent applies universality by creating a general formula I that can generate multiple compounds with different substituent combinations (R1-R6, Q1-Q7) that all share the common M1 receptor positive allosteric modulation function. This universal framework allows a single structural scaffold to serve multiple therapeutic purposes across different disease states (Alzheimer's disease, schizophrenia, cognitive impairment) while maintaining consistent mechanism of action, thereby reducing overall development complexity.
Data Source
AI summary
In one aspect, the invention relates to N-substituted 3,4-dihydro-benzo[£][1,4]oxazine-2-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.